 Presentation will be available on demand as part of the 2021 American Society of Clinical Oncology ASCO Annual Meeting BOSTON, MA and WILMINGTON, DE ACCESSWIRE June 4, 2021 MorphoSys US Inc., a fully owned subsidiary of MorphoSys AG FSE:MOR NASDAQ:MOR, and Incyte NASDAQ:INCY today announced new three-year follow-up data from the ongoing Phase 2 L-MIND study of tafasitamab MonjuviR in combination with lenalidomide in adult patients with relapsed or refractory diffuse large B-cell lymphoma DLBCL. A total of 80 out of 81 enrolled study patients receiving tafasitamab plus lenalidomide were included in the efficacy analysis at approximately three years follow-up 35 months. 